NC-MZFY
NetraPharma
AI, clinical trial design, patient stratification
measurementoperating trials
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companies
AI, clinical trial design, patient stratification
0-100 chain-logic scale · 15 dimensions · scored on public evidence
NetraPharma AI, clinical trial design, patient stratification
NetraMark develops NetraAI, an AI platform for clinical development teams seeking to optimize trial design and late-stage decision-making. The site says NetraAI uses Attractor AI, a proprietary long-range attractor algorithm, to identify hidden patient correlations, treatment efficacy, toxicity, placebo response, and causal variables of patient response. Its technology is positioned for enrichment, inclusion/exclusion criteria design, disease heterogeneity analysis, and smaller, more efficient Phase III studies.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
NetraPharma — Translational · Bottom quartile. Derived deterministically from 8 extracted project(s). Most-advanced status: phase 2. Band: translational. Aging-relevance not LLM-reviewed in this pass.
Source: Deterministic